US20220249491A1 - Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor - Google Patents

Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor Download PDF

Info

Publication number
US20220249491A1
US20220249491A1 US17/617,530 US202017617530A US2022249491A1 US 20220249491 A1 US20220249491 A1 US 20220249491A1 US 202017617530 A US202017617530 A US 202017617530A US 2022249491 A1 US2022249491 A1 US 2022249491A1
Authority
US
United States
Prior art keywords
solid tablet
oral administration
zanubrutinib
administration according
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/617,530
Inventor
Gang Qiu
Yiwei SHEN
Wenyuan FAN
Shuo XU
Huiru LV
Jialin BIAN
Zhengming Du
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beigene Switzerland GmbH
Original Assignee
Beigene Switzerland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Switzerland GmbH filed Critical Beigene Switzerland GmbH
Assigned to BEIGENE SWITZERLAND GMBH reassignment BEIGENE SWITZERLAND GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BEIGENE, LTD.
Assigned to BEIGENE, LTD. reassignment BEIGENE, LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHEN, Yiwei, LV, Huiru, BIAN, Jialin, DU, ZHENGMING, FAN, WENYUAN, QIU, GANG, XU, Shuo
Publication of US20220249491A1 publication Critical patent/US20220249491A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to an solid tablet for oral administration containing a Bruton's Tyrosine Kinase (BTK) inhibitor, in particular (S)-7-[4-(1-acryloylpiperidine)]-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and a preparation method thereof.
  • BTK Bruton's Tyrosine Kinase
  • BTK Bruton's Tyrosine Kinase
  • S-7-[4-(1-acryloylpiperidine)]-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a] pyrimidine-3-carboxamide (with a generic name of Zanubrutinib), which has a chemical structure as follows:
  • Zanubrutinib belongs to the second-generation BTK inhibitor, which irreversibly inactivates the tyrosine kinase by covalently binding with the enzyme. It is used as a single agent or in combination with other drugs for the treatment of B lymphocyte tumors, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), follicular lymphoma (FL), non-germinal center subtype diffuse large B-cell lymphoma (non-GCB DLBCL), etc.
  • CLL/SLL chronic lymphocytic leukemia/small lymphocytic lymphoma
  • MCL mantle cell lymphoma
  • WM Waldenstrom's macroglobulinemia
  • FL follicular lymphoma
  • non-GCB DLBCL non-germinal center subtype diffuse large B-cell lymphoma
  • the active pharmaceutical ingredient of Zanubrutinib is slightly hygroscopic. DSC results show that the compound has a distinct endothermic peak when it melts, and has an initial temperature and a peak temperature of 139° C. and 144° C., respectively.
  • the melting point of the active pharmaceutical ingredient is 145° C., which is lower than the ideal melting point of 150° C. for tablet development, and the material is relatively viscous, which poses a huge challenge to the development and large-scale industrial production of Zanubrutinib tablets.
  • the Zanubrutinib has a pH-dependent solubility and belongs to class II (low solubility, and high permeability) drug of the biopharmaceutical classification system. Therefore, there is an urgent need to develop a Zanubrutinib tablet in which the active ingredient can dissolve quickly from the preparation, so as to maintain the rapid release of the drug in the whole intestine with good bioavailability.
  • the present invention provides an solid tablet for oral administration containing Bruton's Tyrosine Kinase inhibitor of Zanubrutinib and a preparation method thereof.
  • the inventors of the present invention unexpectedly discovered that a certain amount of colloidal silica as a glidant and other excipients have a significant contribution to improve the sticking of the drug and ensure a good dissolution rate of the drug.
  • the solid tablet for oral administration of Zanubrutinib of the present invention can be released relatively quickly in a medium containing sodium lauryl sulfate at pH 1.2 (HCl), for example, the dissolution rate can reach more than 80% within 30 to 60 min at some prescription excipient ratios; preferably, the dissolution rate of Zanubrutinib can reach more than 95% within 30 min at some prescription excipient ratios.
  • the solid tablet for oral administration of Zanubrutinib of the present invention has no special requirements for production equipment, has a simple preparation process, a stable product, and low production costs.
  • an solid tablet for oral administration containing Zanubrutinib comprising: (1) 20% to 70% (mass percentage), preferably 30% to 50% (mass percentage) of Zanubrutinib; and (2) one or more pharmaceutically acceptable excipients.
  • the Zanubrutinib may be in any solid form thereof, such as a crystal form (e.g., crystal form A disclosed in WO 2018033853 A), an amorphous form, or a mixture of a crystal form and an amorphous form.
  • the solid tablet for oral administration is of a crystal form A, an amorphous form, or a mixture of a crystal form A and an amorphous form.
  • the particle size of the Zanubrutinib is no more than 40 ⁇ m.
  • the X-ray powder diffraction pattern of crystal form A includes diffraction peaks having 2 ⁇ angle values independently selected from: about 14.8 ⁇ 0.2°, 15.6 ⁇ 0.2°, 16.4 ⁇ 0.2° and 21.4 ⁇ 0.2°. In some embodiments, the X-ray powder diffraction pattern of crystal form A includes diffraction peaks having 2 ⁇ angle values independently selected from: about 12.2 ⁇ 0.2°, 12.9 ⁇ 0.2°, 14.8 ⁇ 0.2°, 15.6 ⁇ 0.2°, 16.4 ⁇ 0.2° and 21.4 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of crystal form A includes diffraction peaks having 2 ⁇ angle values independently selected from: about 12.2 ⁇ 0.2°, 12.9 ⁇ 0.2°, 14.8 ⁇ 0.2°, 15.6 ⁇ 0.2°, 16.4 ⁇ 0.2°, 17.7 ⁇ 0.2°, 18.5 ⁇ 0.2°, 20.7 ⁇ 0.2° and 21.4 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of crystal form A is substantially consistent with FIG. 1 .
  • the excipient is optionally selected from a filler, a binder, a disintegrant, a wetting agent, a glidant, a lubricant, and any combination thereof.
  • the filler is selected from starch, sucrose, microcrystalline cellulose, mannitol, lactose, pre gelatinized starch, glucose, maltodextrin, cyclodextrin, cellulose, silicified microcrystalline cellulose, and any combination thereof.
  • the filler is lactose in a content of about 20% to 70%, preferably about 40% to 60%, all in mass percentages.
  • the filler is microcrystalline cellulose
  • the microcrystalline cellulose is internal filler
  • the content of the microcrystalline cellulose filler is about 10% to 50%, preferably about 30% to 50%, all in mass percentages.
  • the filler is a combination of lactose and microcrystalline cellulose, and the contents of the lactose and the microcrystalline cellulose are about 0% to 70% and about 0% to 50%, preferably about 40% to 60% and about 4% to 10%, respectively, all in mass percentages.
  • the binder is selected from starch, hypromellose, polyvinylpyrrolidone, sodium carboxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, gelatin, sucrose, and any combination thereof.
  • the binder is hypromellose, and the content of the hypromellose is about 0% to 10%, preferably about 0% to 5%, all in mass percentages.
  • the binder is croscarmellose sodium in a content of about 0% to 10%, preferably about 0% to 5%, all in mass percentages.
  • the disintegrant is selected from sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, crospovidone, croscarmellose sodium, croscarmellose, methyl cellulose, pregelatinized starch, sodium alginate, and any combination thereof.
  • the disintegrant is croscarmellose sodium
  • the content of the croscarmellose sodium is about 0.5% to 5%, preferably about 1% to 3%, all in mass percentages.
  • the wetting agent is sodium lauryl sulfate (SLS), and the content of the sodium lauryl sulfate is about 0% to 5%, preferably about 0.5% to 1.0%, all in mass percentages.
  • SLS sodium lauryl sulfate
  • the glidant is selected from powdered cellulose, magnesium trisilicate, colloidal silica, talc powder, and any combination thereof.
  • the glidant is colloidal silica
  • the content of the colloidal silica is about 0.1% to 20%, which is mass percentage.
  • the content of the colloidal silica is less than 0.1% (mass percentage)
  • colloidal silica cannot effectively disperse the API, as a result, the rapid disintegration of the tablets and the dissolution of the API cannot be guaranteed;
  • the content of the colloidal silica is greater than 20% (mass percentage)
  • the content of the colloidal silica is about 4% to 8%, in mass percentage.
  • the lubricant is selected from zinc stearate, glyceryl monostearate, glyceryl palmitate stearate, magnesium stearate, sodium fumarate stearate, and any combination thereof.
  • the lubricant is magnesium stearate in a content of about 0.1% to 2%, preferably about 0.3% to 1%, all in mass percentages.
  • the Zanubrutinib solid tablet for oral administration provided by the present invention further comprises a coating agent.
  • the coating agent is selected from an Opadry film coating powder, polyvinyl alcohol, hydroxypropyl cellulose, polyethylene glycol, and any combination thereof.
  • the Opadry film coating powder is preferred.
  • the present invention provides a method for preparing the Zanubrutinib oral solid preparation, and the granulation process of which is selected from direct powder compression, dry granulation, and wet granulation, preferably wet granulation.
  • the present invention provides a method for preparing the Zanubrutinib solid tablet for oral administration, which comprises the following steps:
  • a Zanubrutinib active pharmaceutical ingredient includes but not limited to, a filler, a binder, a disintegrant, a wetting agent, a glidant, and a lubricant;
  • step (3) optionally, coating the plain tablets, wherein if step (3) is not performed, the sized granules obtained in step (2) are compressed into plain tablets.
  • the organic reagent in step (2) is selected from ethanol, acetone, and a combination thereof.
  • the additional excipient described in step (3) is selected from a filler (e.g., microcrystalline cellulose), a lubricant (e.g., magnesium stearate), a glidant (e.g., colloidal silica), and any combination thereof.
  • a filler e.g., microcrystalline cellulose
  • a lubricant e.g., magnesium stearate
  • a glidant e.g., colloidal silica
  • the “mixing” in the above-mentioned preparation step (1) is carried out by a commonly used mixing method.
  • An apparatus for example, a hopper mixer, a vertical granulator, FLO-5M, V-type mixer, a tumbler mixer, etc., is used for “mixing”.
  • the granulation in the above-mentioned preparation step (2) can be carried out by a common granulation method.
  • the granulation is carried out by an apparatus, such as a wet granulator, etc.
  • the compression is carried out by a conventional tablet press, such as ZP10A. After the tablet is made, it can be “dried”, if necessary.
  • any method used to dry the preparation can generally be used, for example, vacuum drying, fluidized bed drying, etc.
  • any method used to dry the preparation can generally be used, for example, vacuum drying, fluidized bed drying, etc.
  • the term “mass percentage” describes the contents of the Zanubrutinib active pharmaceutical ingredient and various excipients, which is calculated with respect to the total mass of the solid tablet for oral administration.
  • preparation refers to a mixture, an aggregate, a solution or other combinations of substances including the active pharmaceutical ingredients (APIs); the preparation is suitable for a particular route of administration, for example, is suitable for compression into a preparation of a tablet that is designed for oral administration in the treatment, management, and prevention, etc., of the patient's disease states or disorders.
  • APIs active pharmaceutical ingredients
  • the “coating” as used herein is not limited to the case of coating the entire surface of the coated object (a plain tablet containing Zanubrutinib), but can also refers to the partial coating of the coated object, absorbing or adsorbing the enteric-coating components onto the coated object, or plain tablets with an inner core coated.
  • the solid tablet for oral administrations prepared according to the present invention have a hardness of 60 N to 220 N, and the dissolution rate exceeds 85% within 30 minutes.
  • the content of Zanubrutinib in the solid oral tablet is usually about 70 mg to about 400 mg of Zanubrutinib per tablet, preferably about 80 mg, 160 mg or 320 mg of Zanubrutinib.
  • the solid oral tablet may also contain one or more agents selected from a sweetening agent, a corrective, a colouring agent and a preservative to provide a pharmaceutically aesthetic and palatable preparation.
  • the solid oral tablet can be prepared in a variety of possible shapes (ellipsoid, capsule, double-sided convex round lamp).
  • FIG. 1 is an X-ray powder diffraction pattern of the crystal form A of Zanubrutinib.
  • FIG. 2 is a schematic diagram of the cumulative drug dissolution (in vitro dissolution) of the solid tablet for oral administrations of Zanubrutinib in Example 1.
  • FIG. 3 is a schematic diagram of the cumulative drug dissolution (in vitro dissolution) of the solid tablet for oral administrations of Zanubrutinib in Example 8 and Example 9. It can be seen therefrom that the drug dissolution rate of Example 8 is significantly better than that of Example 9.
  • the temperature is in ° C.
  • Reagents are purchased from commercial providers such as Sigma-Aldrich, Alfa Aesar or TCI, and can be used without further purification unless otherwise specified.
  • Zanubrutinib (Crystal form A) 34.8 g Lactose 53.2 g Croscarmellose sodium 2 g Colloidal silica 4.5 g Sodium lauryl sulfate 1 g Microcrystalline cellulose 4 g Magnesium stearate 0.5 g Opadry 2.4 g
  • Preparation Process 53.2 g of lactose, 2 g of croscarmellose sodium, 1 g of sodium lauryl sulfate and 34.8 g of Zanubrutinib are added into a high-shear granulator (MYCROMIX, manufactured by BOSCH) and mixed for 5 minutes, an appropriate amount of purified water is added for granulation, followed by dying and then sizing, 4.5 g of colloidal silica, 4 g of microcrystalline cellulose and 0.5 g of magnesium stearate are further added and mixed. After mixing, the above ingredients are pressed into tablets to obtain plain tablets. The above-mentioned plain tablets are coated with 2.4 g of Opadry to obtain solid tablet for oral administrations containing Zanubrutinib.
  • MYCROMIX high-shear granulator
  • the in vitro dissolution experiment is determined by an automatic sampling dissolution tester (Model: 708+850DS, purchased from AGILENT), according to USP ⁇ 711>, the “dissolution” is determined using the basket method, the automatic sampling dissolution tester is set at a water bath temperature of 37 ⁇ 0.5° C., at a rotating speed of 100 rpm, with a pH 1.2 (HCl)+0.5% SLS dissolution medium of a volume of 900 mL. Samples are taken at 10 min, 15 min, 30 min, 45 min, and 60 min, and all samples are passed through a 0.45 ⁇ m filter membrane, and the samples are determined and analyzed according to the sample dissolution test method. As shown in FIG.
  • Zanubrutinib solid tablet for oral administration of the present invention when the Zanubrutinib solid tablet for oral administration of the present invention is in a pH 1.2 (HCl)+0.5% SLS medium, more than 90% of Zanubrutinib is dissolved at 30 minutes, which can meet the requirements of rapid release.
  • Example 2-12 the drug cumulative dissolution (in vitro dissolution) are all measured according to the method of Example 1.
  • Zanubrutinib (Crystal form A) 36.2 g Lactose 55.6 g Croscarmellose sodium 2.2 g Colloidal silica 4.3 g Sodium lauryl sulfate 1.1 g Magnesium stearate 0.5 g
  • Preparation Process 55.6 g of lactose, 2.2 g of croscarmellose sodium, 1.1 g of sodium lauryl sulfate, 4.3 g of colloidal silica and 36.2 g of Zanubrutinib are added into a high-shear granulator and mixed for 5 minutes, an appropriate amount of purified water is added for granulation, followed by dying and then sizing, and 0.5 g of magnesium stearate is further added and mixed. After mixing, the above ingredients are pressed into tablets to obtain plain tablets, that is, an solid tablet for oral administration containing Zanubrutinib.
  • Zanubrutinib (Crystal form A) 33.3 g Lactose 49.2 g Hypromellose 2 g Croscarmellose sodium 2 g Colloidal silica 4 g Sodium lauryl sulfate 1 g Microcrystalline cellulose 8 g Magnesium stearate 0.5 g
  • Preparation Process 49.2 g of lactose, 2 g of croscarmellose sodium, 1 g of sodium lauryl sulfate and 33.3 g of Zanubrutinib are added into a high-shear granulator and mixed for 5 minutes, 2 g of hypromellose aqueous solution is added for granulation, followed by dying and then sizing, 4 g of colloidal silica, 8 g of microcrystalline cellulose and 0.5 g of magnesium stearate are further added and mixed. After mixing, the above ingredients are pressed into tablets to obtain plain tablets, that is, an solid tablet for oral administration containing Zanubrutinib.
  • Zanubrutinib (Crystal form A) 50 g Croscarmellose sodium 4 g Colloidal silica 12.0 g Sodium lauryl sulfate 1 g Microcrystalline cellulose 32.5 g Magnesium stearate 0.5 g Opadry 1.5 g
  • Preparation Process 50 g of Zanubrutinib, 4 g of croscarmellose sodium, 12.0 g of colloidal silica, 1 g of sodium lauryl sulfate, 32.5 g of microcrystalline cellulose are sieved and then mixed in a high-shear granulator, then 0.5 g of magnesium stearate is added and mixed uniformly. The mixed powder is pressed directly to obtain plain tablets. The above-mentioned plain tablets are coated with a coating liquid containing 2.4 g of Opadry to obtain solid tablet for oral administrations containing Zanubrutinib.
  • Drug Cumulative Dissolution (In Vitro Dissolution) Test The dissolution rate (%) of the drug at 30 minutes is about 80%.
  • Zanubrutinib (Crystal form A) 26.7 g Lactose 23.8 g Croscarmellose sodium 2 g Colloidal silica 4 g Sodium lauryl sulfate 1 g Microcrystalline cellulose 40 g Hypromellose 2 g Magnesium stearate 0.5 g Opadry 1.5 g
  • Preparation Process 23.8 g of lactose, 40 g of microcrystalline cellulose, 2 g of croscarmellose sodium, 1 g of sodium lauryl sulfate, 4 g of colloidal silica, and 26.7 g of Zanubrutinib are added to a fluidized bed, then 2 g of a hypromellose aqueous solution is sprayed for granulation, followed by drying and then magnesium stearate is added and mixed. After mixing, the above ingredients are pressed into tablets to obtain plain tablets. The above-mentioned plain tablets are coated with a coating liquid containing 1.5 g of Opadry to obtain solid tablet for oral administrations containing Zanubrutinib.
  • Zanubrutinib (Crystal form A) 26.7 g Lactose 35.8 g Croscarmellose sodium 2 g Colloidal silica 4 g Sodium lauryl sulfate 1 g Silicified microcrystalline cellulose 30 g Magnesium stearate 0.5 g
  • Preparation Process 26.7 g of Zanubrutinib, 2 g of croscarmellose sodium, 4 g of colloidal silica, 1 g of sodium lauryl sulfate, 35.8 g of lactose and 30 g of silicified microcrystalline cellulose are sieved and then mixed in a high-shear granulator, then 0.5 g of magnesium stearate is added and mixed uniformly. The powder is pressed into tablets directly, coated with an Opadry coating liquid to obtain solid tablet for oral administrations containing Zanubrutinib.
  • Zanubrutinib (Crystal form A) 50.0 g Lactose 36.5 g Croscarmellose sodium 4 g Colloidal silica 8 g Sodium lauryl sulfate 1 g Magnesium stearate 0.5 g
  • Preparation Process 50.0 g of Zanubrutinib, 4 g of croscarmellose sodium, 8 g of colloidal silica, 1 g of sodium lauryl sulfate, 36.5 g of lactose are sieved and then mixed in a high-shear granulator, then 0.5 g of magnesium stearate is added and mixed uniformly.
  • the powder is pressed directly into tablets to obtain plain tablets, that is, an solid tablet for oral administration containing Zanubrutinib.
  • Drug Cumulative Dissolution (In Vitro Dissolution) Test The dissolution rate (%) of the drug at 30 minutes is about 40%.
  • Zanubrutinib (Crystal form A) 50.0 g Croscarmellose sodium 4 g Colloidal silica 8 g Sodium lauryl sulfate 1 g Microcrystalline cellulose 36.5 g Magnesium stearate 0.5 g
  • Preparation Process 50.0 g of Zanubrutinib, 36.5 g of microcrystalline cellulose, 4 g of croscarmellose sodium, 8 g of colloidal silica, 1 g of sodium lauryl sulfate are sieved and then mixed in a high-shear granulator, then 0.5 g of magnesium stearate is added and mixed uniformly.
  • the powder is pressed directly into tablets to obtain plain tablets, that is, an solid tablet for oral administration containing Zanubrutinib.
  • Drug Cumulative Dissolution (In Vitro Dissolution) Test The dissolution curve of the drug is shown in FIG. 3 . It can be seen that the dissolution is greater than 80% at 30 minutes.
  • Zanubrutinib (Crystal form A) 60.0 g Croscarmellose sodium 4 g Colloidal silica 0.8 g Sodium lauryl sulfate 1 g Microcrystalline cellulose 33.7 g Magnesium stearate 0.5 g
  • Preparation Process 60 g of Zanubrutinib, 33.7 g of microcrystalline cellulose, 4 g of croscarmellose sodium, 0.8 g of colloidal silica, 1 g of sodium lauryl sulfate are sieved and then mixed in a high-shear granulator, then 0.5 g of magnesium stearate is added and mixed uniformly.
  • the powder is pressed directly into tablets to obtain plain tablets, that is, an solid tablet for oral administration containing Zanubrutinib.
  • Drug Cumulative Dissolution (In Vitro Dissolution) Test The dissolution curve of the drug is shown in FIG. 3 . It can be seen that the dissolution is less than 60% at 30 minutes.
  • Zanubrutinib (Crystal form A) 46.69 g Croscarmellose sodium 4.38 g Colloidal silica 0.88 g Sodium lauryl sulfate 0.88 g Microcrystalline cellulose 46.69 g Magnesium stearate 0.50 g
  • Preparation Process 53.2 g of lactose, 2 g of croscarmellose sodium, 1 g of sodium lauryl sulfate and 34.8 g of Zanubrutinib are added into a high-shear granulator (MYCROMIX, manufactured by BOSCH) and mixed for 5 minutes, an appropriate amount of purified water is added for granulation, followed by dying and then sizing, 4.5 g of colloidal silica, 4 g of microcrystalline cellulose and 0.5 g of magnesium stearate are further added and mixed. After mixing, the above ingredients are pressed into tablets to obtain plain tablets, that is, an solid tablet for oral administration containing Zanubrutinib.
  • MYCROMIX high-shear granulator
  • Drug Cumulative Dissolution (In Vitro Dissolution) Test The dissolution rate (%) of the drug at 60 minutes is about 80%.
  • Zanubrutinib (Crystal form A) 46.69 g Lactose 46.69 g Croscarmellose sodium 4.38 g Colloidal silica 0.88 g Sodium lauryl sulfate 0.88 g Magnesium stearate 0.50 g
  • Drug Cumulative Dissolution (In Vitro Dissolution) Test The dissolution rate (%) of the drug at 60 minutes is less than 80%.
  • Zanubrutinib (Crystal form A) 22.21 g Croscarmellose sodium 3.00 g Colloidal silica 0.50 g Sodium lauryl sulfate 0.50 g Microcrystalline cellulose 73.29 g Magnesium stearate 0.50 g

Abstract

Provided are an oral solid tablet comprising (S)-7-[4-(1-acryloylpiperidine)]-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and preparation method therefor. The oral solid tablet has good drug release characteristics, features easy administration, quick and high-efficient release, no particular requirements on equipment, and a simple formulation preparation process, can ensure formulation stability and facilitate transportation and storage, and is suitable for large-scale production.

Description

    TECHNICAL FIELD
  • The present invention relates to an solid tablet for oral administration containing a Bruton's Tyrosine Kinase (BTK) inhibitor, in particular (S)-7-[4-(1-acryloylpiperidine)]-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and a preparation method thereof.
    • BACKGROUND ART
  • International application WO 2014173289 A disclosed a novel Bruton's Tyrosine Kinase (BTK), more particularly (S)-7-[4-(1-acryloylpiperidine)]-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a] pyrimidine-3-carboxamide (with a generic name of Zanubrutinib), which has a chemical structure as follows:
  • Figure US20220249491A1-20220811-C00001
  • Zanubrutinib belongs to the second-generation BTK inhibitor, which irreversibly inactivates the tyrosine kinase by covalently binding with the enzyme. It is used as a single agent or in combination with other drugs for the treatment of B lymphocyte tumors, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), follicular lymphoma (FL), non-germinal center subtype diffuse large B-cell lymphoma (non-GCB DLBCL), etc.
  • The active pharmaceutical ingredient of Zanubrutinib is slightly hygroscopic. DSC results show that the compound has a distinct endothermic peak when it melts, and has an initial temperature and a peak temperature of 139° C. and 144° C., respectively. The melting point of the active pharmaceutical ingredient is 145° C., which is lower than the ideal melting point of 150° C. for tablet development, and the material is relatively viscous, which poses a huge challenge to the development and large-scale industrial production of Zanubrutinib tablets. In addition, the Zanubrutinib has a pH-dependent solubility and belongs to class II (low solubility, and high permeability) drug of the biopharmaceutical classification system. Therefore, there is an urgent need to develop a Zanubrutinib tablet in which the active ingredient can dissolve quickly from the preparation, so as to maintain the rapid release of the drug in the whole intestine with good bioavailability.
    • SUMMARY OF THE INVENTION
  • In order to overcome the deficiencies in the physicochemical properties of Zanubrutinib active pharmaceutical ingredient (API), such as high viscosity, poor fluidity, and poor solubility, etc., and to ensure good dissolution of the drug, the present invention provides an solid tablet for oral administration containing Bruton's Tyrosine Kinase inhibitor of Zanubrutinib and a preparation method thereof. The inventors of the present invention unexpectedly discovered that a certain amount of colloidal silica as a glidant and other excipients have a significant contribution to improve the sticking of the drug and ensure a good dissolution rate of the drug. The solid tablet for oral administration of Zanubrutinib of the present invention can be released relatively quickly in a medium containing sodium lauryl sulfate at pH 1.2 (HCl), for example, the dissolution rate can reach more than 80% within 30 to 60 min at some prescription excipient ratios; preferably, the dissolution rate of Zanubrutinib can reach more than 95% within 30 min at some prescription excipient ratios. In addition, the solid tablet for oral administration of Zanubrutinib of the present invention has no special requirements for production equipment, has a simple preparation process, a stable product, and low production costs.
  • In one aspect of the present invention, there is provided an solid tablet for oral administration containing Zanubrutinib, comprising: (1) 20% to 70% (mass percentage), preferably 30% to 50% (mass percentage) of Zanubrutinib; and (2) one or more pharmaceutically acceptable excipients.
  • In some embodiments of the present invention, the Zanubrutinib may be in any solid form thereof, such as a crystal form (e.g., crystal form A disclosed in WO 2018033853 A), an amorphous form, or a mixture of a crystal form and an amorphous form. Preferably, the solid tablet for oral administration is of a crystal form A, an amorphous form, or a mixture of a crystal form A and an amorphous form. In some specific embodiments of the present invention, the particle size of the Zanubrutinib is no more than 40 μm.
  • In some embodiments, the X-ray powder diffraction pattern of crystal form A includes diffraction peaks having 2θ angle values independently selected from: about 14.8±0.2°, 15.6±0.2°, 16.4±0.2° and 21.4±0.2°. In some embodiments, the X-ray powder diffraction pattern of crystal form A includes diffraction peaks having 2θ angle values independently selected from: about 12.2±0.2°, 12.9±0.2°, 14.8±0.2°, 15.6±0.2°, 16.4±0.2° and 21.4±0.2°. In some embodiments, the X-ray powder diffraction pattern of crystal form A includes diffraction peaks having 2θ angle values independently selected from: about 12.2±0.2°, 12.9±0.2°, 14.8±0.2°, 15.6±0.2°, 16.4±0.2°, 17.7±0.2°, 18.5±0.2°, 20.7±0.2° and 21.4±0.2°. In some embodiments, the X-ray powder diffraction pattern of crystal form A is substantially consistent with FIG. 1.
  • In some embodiments of the present invention, the excipient is optionally selected from a filler, a binder, a disintegrant, a wetting agent, a glidant, a lubricant, and any combination thereof.
  • In some specific embodiments of the present invention, the filler is selected from starch, sucrose, microcrystalline cellulose, mannitol, lactose, pre gelatinized starch, glucose, maltodextrin, cyclodextrin, cellulose, silicified microcrystalline cellulose, and any combination thereof.
  • In some specific embodiments of the present invention, the filler is lactose in a content of about 20% to 70%, preferably about 40% to 60%, all in mass percentages.
  • In some specific embodiments of the present invention, the filler is microcrystalline cellulose, the microcrystalline cellulose is internal filler, and the content of the microcrystalline cellulose filler is about 10% to 50%, preferably about 30% to 50%, all in mass percentages.
  • In some specific embodiments of the present invention, the filler is a combination of lactose and microcrystalline cellulose, and the contents of the lactose and the microcrystalline cellulose are about 0% to 70% and about 0% to 50%, preferably about 40% to 60% and about 4% to 10%, respectively, all in mass percentages.
  • In some embodiments of the present invention, the binder is selected from starch, hypromellose, polyvinylpyrrolidone, sodium carboxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, gelatin, sucrose, and any combination thereof.
  • In some specific embodiments of the present invention, the binder is hypromellose, and the content of the hypromellose is about 0% to 10%, preferably about 0% to 5%, all in mass percentages.
  • In some specific embodiments of the present invention, the binder is croscarmellose sodium in a content of about 0% to 10%, preferably about 0% to 5%, all in mass percentages.
  • In some embodiments of the present invention, the disintegrant is selected from sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, crospovidone, croscarmellose sodium, croscarmellose, methyl cellulose, pregelatinized starch, sodium alginate, and any combination thereof.
  • In some specific embodiments of the present invention, the disintegrant is croscarmellose sodium, and the content of the croscarmellose sodium is about 0.5% to 5%, preferably about 1% to 3%, all in mass percentages.
  • In some embodiments of the present invention, the wetting agent is sodium lauryl sulfate (SLS), and the content of the sodium lauryl sulfate is about 0% to 5%, preferably about 0.5% to 1.0%, all in mass percentages.
  • In some embodiments of the present invention, the glidant is selected from powdered cellulose, magnesium trisilicate, colloidal silica, talc powder, and any combination thereof.
  • In some specific embodiments of the present invention, the glidant is colloidal silica, and the content of the colloidal silica is about 0.1% to 20%, which is mass percentage. When the content of the colloidal silica is less than 0.1% (mass percentage), colloidal silica cannot effectively disperse the API, as a result, the rapid disintegration of the tablets and the dissolution of the API cannot be guaranteed; When the content of the colloidal silica is greater than 20% (mass percentage), it is unfavourable for commercialized production due to its huge volume. More preferably, the content of the colloidal silica is about 4% to 8%, in mass percentage.
  • In some embodiments of the present invention, the lubricant is selected from zinc stearate, glyceryl monostearate, glyceryl palmitate stearate, magnesium stearate, sodium fumarate stearate, and any combination thereof.
  • In some specific embodiments of the present invention, the lubricant is magnesium stearate in a content of about 0.1% to 2%, preferably about 0.3% to 1%, all in mass percentages.
  • Still further, the Zanubrutinib solid tablet for oral administration provided by the present invention further comprises a coating agent.
  • In some embodiments of the present invention, the coating agent is selected from an Opadry film coating powder, polyvinyl alcohol, hydroxypropyl cellulose, polyethylene glycol, and any combination thereof. The Opadry film coating powder is preferred.
  • In one aspect of the present invention, the present invention provides a method for preparing the Zanubrutinib oral solid preparation, and the granulation process of which is selected from direct powder compression, dry granulation, and wet granulation, preferably wet granulation.
  • In one aspect of the present invention, the present invention provides a method for preparing the Zanubrutinib solid tablet for oral administration, which comprises the following steps:
  • (1) mixing a Zanubrutinib active pharmaceutical ingredient and excipients (including but not limited to, a filler, a binder, a disintegrant, a wetting agent, a glidant, and a lubricant);
  • (2) subjecting the mixture of the zanubrutinib active pharmaceutical ingredient and excipients to wet granulation with purified water, or an organic reagent (including but not limited to ethanol, acetone), or an aqueous solution or an organic solution containing a binder, followed by drying and sizing;
  • (3) optionally, mixing the sized granules with an additional excipient (including but not limited to a filler, a lubricant, a glidant) and compressing them into plain tablets;
  • (4) optionally, coating the plain tablets, wherein if step (3) is not performed, the sized granules obtained in step (2) are compressed into plain tablets.
  • In some embodiments of the present invention, the organic reagent in step (2) is selected from ethanol, acetone, and a combination thereof.
  • In some embodiments of the present invention, the additional excipient described in step (3) is selected from a filler (e.g., microcrystalline cellulose), a lubricant (e.g., magnesium stearate), a glidant (e.g., colloidal silica), and any combination thereof.
  • In the above-mentioned preparation method, the specific examples and contents of a filler, a binder, a disintegrant, a wetting agent, a glidant, a lubricant and a coating are as described above.
  • In the above-mentioned preparation method, the “mixing” in the above-mentioned preparation step (1) is carried out by a commonly used mixing method. An apparatus, for example, a hopper mixer, a vertical granulator, FLO-5M, V-type mixer, a tumbler mixer, etc., is used for “mixing”.
  • In the above-mentioned preparation method, the granulation in the above-mentioned preparation step (2) can be carried out by a common granulation method. The granulation is carried out by an apparatus, such as a wet granulator, etc. The compression is carried out by a conventional tablet press, such as ZP10A. After the tablet is made, it can be “dried”, if necessary. For drying, any method used to dry the preparation can generally be used, for example, vacuum drying, fluidized bed drying, etc. The following terms that can be used herein are used according to the following definitions.
  • Unless it is clearly indicated to the contrary, all ranges referred herein are inclusive; that is, the range includes the values of the upper and lower limits of the range and all values therebetween. For example, the temperature range, percentage, equivalent range, etc., described herein include the upper and lower limits of the range and any value in the continuous interval therebetween.
  • As used herein, the term “mass percentage” describes the contents of the Zanubrutinib active pharmaceutical ingredient and various excipients, which is calculated with respect to the total mass of the solid tablet for oral administration.
  • The term “preparation” as used herein refers to a mixture, an aggregate, a solution or other combinations of substances including the active pharmaceutical ingredients (APIs); the preparation is suitable for a particular route of administration, for example, is suitable for compression into a preparation of a tablet that is designed for oral administration in the treatment, management, and prevention, etc., of the patient's disease states or disorders.
  • The “coating” as used herein is not limited to the case of coating the entire surface of the coated object (a plain tablet containing Zanubrutinib), but can also refers to the partial coating of the coated object, absorbing or adsorbing the enteric-coating components onto the coated object, or plain tablets with an inner core coated. The solid tablet for oral administrations prepared according to the present invention have a hardness of 60 N to 220 N, and the dissolution rate exceeds 85% within 30 minutes.
  • In some embodiments of the present invention, the content of Zanubrutinib in the solid oral tablet is usually about 70 mg to about 400 mg of Zanubrutinib per tablet, preferably about 80 mg, 160 mg or 320 mg of Zanubrutinib.
  • In some embodiments of the present invention, the solid oral tablet may also contain one or more agents selected from a sweetening agent, a corrective, a colouring agent and a preservative to provide a pharmaceutically aesthetic and palatable preparation.
  • In some embodiments of the present invention, the solid oral tablet can be prepared in a variety of possible shapes (ellipsoid, capsule, double-sided convex round lamp).
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is an X-ray powder diffraction pattern of the crystal form A of Zanubrutinib.
  • FIG. 2 is a schematic diagram of the cumulative drug dissolution (in vitro dissolution) of the solid tablet for oral administrations of Zanubrutinib in Example 1.
  • FIG. 3 is a schematic diagram of the cumulative drug dissolution (in vitro dissolution) of the solid tablet for oral administrations of Zanubrutinib in Example 8 and Example 9. It can be seen therefrom that the drug dissolution rate of Example 8 is significantly better than that of Example 9.
    •  DETAILED DESCRIPTION OF EMBODIMENTS
  • The following examples can help those skilled in the art to understand the present invention more comprehensively, but do not limit the present invention in any way. In the following, unless otherwise specified, the temperature is in ° C. Reagents are purchased from commercial providers such as Sigma-Aldrich, Alfa Aesar or TCI, and can be used without further purification unless otherwise specified.
    • Example 1
  • Preparation of Solid Tablet for Oral Administrations of Zanubrutinib, Specification: 160 mg
  • Prescription (Per 100 g Plain Tablets):
  •
    Zanubrutinib (Crystal form A) 34.8 g
    Lactose 53.2 g
    Croscarmellose sodium 2 g
    Colloidal silica 4.5 g
    Sodium lauryl sulfate 1 g
    Microcrystalline cellulose 4 g
    Magnesium stearate 0.5 g
    Opadry 2.4 g
  • Preparation Process: 53.2 g of lactose, 2 g of croscarmellose sodium, 1 g of sodium lauryl sulfate and 34.8 g of Zanubrutinib are added into a high-shear granulator (MYCROMIX, manufactured by BOSCH) and mixed for 5 minutes, an appropriate amount of purified water is added for granulation, followed by dying and then sizing, 4.5 g of colloidal silica, 4 g of microcrystalline cellulose and 0.5 g of magnesium stearate are further added and mixed. After mixing, the above ingredients are pressed into tablets to obtain plain tablets. The above-mentioned plain tablets are coated with 2.4 g of Opadry to obtain solid tablet for oral administrations containing Zanubrutinib.
  • Drug Cumulative Dissolution (In Vitro Dissolution) Test: The in vitro dissolution experiment is determined by an automatic sampling dissolution tester (Model: 708+850DS, purchased from AGILENT), according to USP<711>, the “dissolution” is determined using the basket method, the automatic sampling dissolution tester is set at a water bath temperature of 37±0.5° C., at a rotating speed of 100 rpm, with a pH 1.2 (HCl)+0.5% SLS dissolution medium of a volume of 900 mL. Samples are taken at 10 min, 15 min, 30 min, 45 min, and 60 min, and all samples are passed through a 0.45 μm filter membrane, and the samples are determined and analyzed according to the sample dissolution test method. As shown in FIG. 2, when the Zanubrutinib solid tablet for oral administration of the present invention is in a pH 1.2 (HCl)+0.5% SLS medium, more than 90% of Zanubrutinib is dissolved at 30 minutes, which can meet the requirements of rapid release.
  • In the following Examples 2-12, the drug cumulative dissolution (in vitro dissolution) are all measured according to the method of Example 1.
    • Example 2
  • Preparation of Solid Tablet for Oral Administrations of Zanubrutinib, Specification: 160 mg
  • Prescription (Per 100 g Plain Tablets):
  •
    Zanubrutinib (Crystal form A) 36.2 g
    Lactose 55.6 g
    Croscarmellose sodium 2.2 g
    Colloidal silica 4.3 g
    Sodium lauryl sulfate 1.1 g
    Magnesium stearate 0.5 g
  • Preparation Process: 55.6 g of lactose, 2.2 g of croscarmellose sodium, 1.1 g of sodium lauryl sulfate, 4.3 g of colloidal silica and 36.2 g of Zanubrutinib are added into a high-shear granulator and mixed for 5 minutes, an appropriate amount of purified water is added for granulation, followed by dying and then sizing, and 0.5 g of magnesium stearate is further added and mixed. After mixing, the above ingredients are pressed into tablets to obtain plain tablets, that is, an solid tablet for oral administration containing Zanubrutinib.
  • Drug Cumulative Dissolution (In Vitro Dissolution) Test: About 90% of Zanubrutinib is dissolved at 30 minutes.
    • Example 3
  • Preparation of Solid Tablet for Oral Administrations of Zanubrutinib, Specification: 160 mg
  • Prescription (Per 100 g Plain Tablets):
  •
    Zanubrutinib (Crystal form A) 33.3 g
    Lactose 49.2 g
    Hypromellose 2 g
    Croscarmellose sodium 2 g
    Colloidal silica 4 g
    Sodium lauryl sulfate 1 g
    Microcrystalline cellulose 8 g
    Magnesium stearate 0.5 g
  • Preparation Process: 49.2 g of lactose, 2 g of croscarmellose sodium, 1 g of sodium lauryl sulfate and 33.3 g of Zanubrutinib are added into a high-shear granulator and mixed for 5 minutes, 2 g of hypromellose aqueous solution is added for granulation, followed by dying and then sizing, 4 g of colloidal silica, 8 g of microcrystalline cellulose and 0.5 g of magnesium stearate are further added and mixed. After mixing, the above ingredients are pressed into tablets to obtain plain tablets, that is, an solid tablet for oral administration containing Zanubrutinib.
    • Example 4
  • Preparation of Solid Tablet for Oral Administrations of Zanubrutinib, Specification: 320 mg
  • Prescription (Per 100 g Plain Tablets):
  •
    Zanubrutinib (Crystal form A) 50 g
    Croscarmellose sodium 4 g
    Colloidal silica 12.0 g
    Sodium lauryl sulfate 1 g
    Microcrystalline cellulose 32.5 g
    Magnesium stearate 0.5 g
    Opadry 1.5 g
  • Preparation Process: 50 g of Zanubrutinib, 4 g of croscarmellose sodium, 12.0 g of colloidal silica, 1 g of sodium lauryl sulfate, 32.5 g of microcrystalline cellulose are sieved and then mixed in a high-shear granulator, then 0.5 g of magnesium stearate is added and mixed uniformly. The mixed powder is pressed directly to obtain plain tablets. The above-mentioned plain tablets are coated with a coating liquid containing 2.4 g of Opadry to obtain solid tablet for oral administrations containing Zanubrutinib.
  • Drug Cumulative Dissolution (In Vitro Dissolution) Test: The dissolution rate (%) of the drug at 30 minutes is about 80%.
    • Example 5
  • Preparation of Solid Tablet for Oral Administrations of Zanubrutinib, Specification: 80 mg
  • Prescription (Per 100 g Plain Tablets):
  •
    Zanubrutinib (Crystal form A) 26.7 g
    Lactose 23.8 g
    Croscarmellose sodium 2 g
    Colloidal silica 4 g
    Sodium lauryl sulfate 1 g
    Microcrystalline cellulose 40 g
    Hypromellose 2 g
    Magnesium stearate 0.5 g
    Opadry 1.5 g
  • Preparation Process: 23.8 g of lactose, 40 g of microcrystalline cellulose, 2 g of croscarmellose sodium, 1 g of sodium lauryl sulfate, 4 g of colloidal silica, and 26.7 g of Zanubrutinib are added to a fluidized bed, then 2 g of a hypromellose aqueous solution is sprayed for granulation, followed by drying and then magnesium stearate is added and mixed. After mixing, the above ingredients are pressed into tablets to obtain plain tablets. The above-mentioned plain tablets are coated with a coating liquid containing 1.5 g of Opadry to obtain solid tablet for oral administrations containing Zanubrutinib.
    • Example 6
  • Preparation of Solid Tablet for Oral Administrations of Zanubrutinib, Specification: 80 mg
  • Prescription (Per 100 g Plain Tablets):
  •
    Zanubrutinib (Crystal form A) 26.7 g
    Lactose 35.8 g
    Croscarmellose sodium 2 g
    Colloidal silica 4 g
    Sodium lauryl sulfate 1 g
    Silicified microcrystalline cellulose 30 g
    Magnesium stearate 0.5 g
  • Preparation Process: 26.7 g of Zanubrutinib, 2 g of croscarmellose sodium, 4 g of colloidal silica, 1 g of sodium lauryl sulfate, 35.8 g of lactose and 30 g of silicified microcrystalline cellulose are sieved and then mixed in a high-shear granulator, then 0.5 g of magnesium stearate is added and mixed uniformly. The powder is pressed into tablets directly, coated with an Opadry coating liquid to obtain solid tablet for oral administrations containing Zanubrutinib.
    • Example 7
  • Preparation of Solid Tablet for Oral Administrations of Zanubrutinib, Specification: 320 mg
  • Prescription (Per 100 g Plain Tablets):
  •
    Zanubrutinib (Crystal form A) 50.0 g
    Lactose 36.5 g
    Croscarmellose sodium 4 g
    Colloidal silica 8 g
    Sodium lauryl sulfate 1 g
    Magnesium stearate 0.5 g
  • Preparation Process: 50.0 g of Zanubrutinib, 4 g of croscarmellose sodium, 8 g of colloidal silica, 1 g of sodium lauryl sulfate, 36.5 g of lactose are sieved and then mixed in a high-shear granulator, then 0.5 g of magnesium stearate is added and mixed uniformly. The powder is pressed directly into tablets to obtain plain tablets, that is, an solid tablet for oral administration containing Zanubrutinib.
  • Drug Cumulative Dissolution (In Vitro Dissolution) Test: The dissolution rate (%) of the drug at 30 minutes is about 40%.
    • Example 8
  • Preparation of Solid Tablet for Oral Administrations of Zanubrutinib, Specification: 320 mg
  • Prescription (Per 100 g Plain Tablets):
  •
    Zanubrutinib (Crystal form A) 50.0 g
    Croscarmellose sodium 4 g
    Colloidal silica 8 g
    Sodium lauryl sulfate 1 g
    Microcrystalline cellulose 36.5 g
    Magnesium stearate 0.5 g
  • Preparation Process: 50.0 g of Zanubrutinib, 36.5 g of microcrystalline cellulose, 4 g of croscarmellose sodium, 8 g of colloidal silica, 1 g of sodium lauryl sulfate are sieved and then mixed in a high-shear granulator, then 0.5 g of magnesium stearate is added and mixed uniformly. The powder is pressed directly into tablets to obtain plain tablets, that is, an solid tablet for oral administration containing Zanubrutinib.
  • Drug Cumulative Dissolution (In Vitro Dissolution) Test: The dissolution curve of the drug is shown in FIG. 3. It can be seen that the dissolution is greater than 80% at 30 minutes.
    • Example 9
  • Preparation of Solid Tablet for Oral Administrations of Zanubrutinib, Specification: 320 mg
  • Prescription (Per 100 g Plain Tablets):
  •
    Zanubrutinib (Crystal form A) 60.0 g
    Croscarmellose sodium 4 g
    Colloidal silica 0.8 g
    Sodium lauryl sulfate 1 g
    Microcrystalline cellulose 33.7 g
    Magnesium stearate 0.5 g
  • Preparation Process: 60 g of Zanubrutinib, 33.7 g of microcrystalline cellulose, 4 g of croscarmellose sodium, 0.8 g of colloidal silica, 1 g of sodium lauryl sulfate are sieved and then mixed in a high-shear granulator, then 0.5 g of magnesium stearate is added and mixed uniformly. The powder is pressed directly into tablets to obtain plain tablets, that is, an solid tablet for oral administration containing Zanubrutinib.
  • Drug Cumulative Dissolution (In Vitro Dissolution) Test: The dissolution curve of the drug is shown in FIG. 3. It can be seen that the dissolution is less than 60% at 30 minutes.
    • Example 10
  • Preparation of Solid Tablet for Oral Administrations of Zanubrutinib, Specification: 320 mg
  • Prescription (Per 100 g Plain Tablets):
  •
    Zanubrutinib (Crystal form A) 46.69 g
    Croscarmellose sodium 4.38 g
    Colloidal silica 0.88 g
    Sodium lauryl sulfate 0.88 g
    Microcrystalline cellulose 46.69 g
    Magnesium stearate 0.50 g
  • Preparation Process: 53.2 g of lactose, 2 g of croscarmellose sodium, 1 g of sodium lauryl sulfate and 34.8 g of Zanubrutinib are added into a high-shear granulator (MYCROMIX, manufactured by BOSCH) and mixed for 5 minutes, an appropriate amount of purified water is added for granulation, followed by dying and then sizing, 4.5 g of colloidal silica, 4 g of microcrystalline cellulose and 0.5 g of magnesium stearate are further added and mixed. After mixing, the above ingredients are pressed into tablets to obtain plain tablets, that is, an solid tablet for oral administration containing Zanubrutinib.
  • Drug Cumulative Dissolution (In Vitro Dissolution) Test: The dissolution rate (%) of the drug at 60 minutes is about 80%.
    • Example 11
  • Preparation of Solid Tablet for Oral Administrations of Zanubrutinib, Specification: 320 mg
  • Prescription (Per 100 g Plain Tablets):
  •
    Zanubrutinib (Crystal form A) 46.69 g
    Lactose 46.69 g
    Croscarmellose sodium 4.38 g
    Colloidal silica 0.88 g
    Sodium lauryl sulfate 0.88 g
    Magnesium stearate 0.50 g
  • Preparation Process: According to a method similar to Example 10, the solid tablet for oral administrations containing Zanubrutinib can be prepared.
  • Drug Cumulative Dissolution (In Vitro Dissolution) Test: The dissolution rate (%) of the drug at 60 minutes is less than 80%.
    • Example 12
  • Preparation of Solid Tablet for Oral Administrations of Zanubrutinib, Specification: 320 mg
  • Prescription (Per 100 g Plain Tablets):
  •
    Zanubrutinib (Crystal form A) 22.21 g
    Croscarmellose sodium 3.00 g
    Colloidal silica 0.50 g
    Sodium lauryl sulfate 0.50 g
    Microcrystalline cellulose 73.29 g
    Magnesium stearate 0.50 g
  • Preparation Process: According to a method similar to Example 10, the solid tablet for oral administrations containing Zanubrutinib can be prepared.
  • Although the foregoing description teaches the principles of the present invention and provides examples for the purpose of illustration, the practice of the present invention includes all common changes, adaptations and/or modifications within the scope of the following claims. The references involved in this disclosure are incorporated herein by reference.

Claims (21)

What is claimed is:
1. An solid tablet for oral administration containing Zanubrutinib, comprising: (1) 20% to 70%, preferably 30% to 50% of Zanubrutinib, all in mass percentages; and (2) one or more pharmaceutically acceptable excipients.
2. The solid tablet for oral administration according to claim 1, wherein the Zanubrutinib is of a crystal form A, an amorphous form, or a mixture of a crystal form A and an amorphous form.
3. The solid tablet for oral administration according to claim 1 or 2, wherein the excipient is selected from a filler, a binder, a disintegrant, a wetting agent, a glidant, a lubricant, and any combination thereof.
4. The solid tablet for oral administration according to claim 3, wherein the filler is selected from starch, sucrose, microcrystalline cellulose, mannitol, lactose, pregelatinized starch, glucose, maltodextrin, cyclodextrin, cellulose, silicified microcrystalline cellulose, and any combination thereof.
5. The solid tablet for oral administration according to claim 4, wherein the filler is lactose, and the content of the lactose is 20% to 70%, preferably 40% to 60%, all in mass percentages.
6. The solid tablet for oral administration according to claim 4, wherein the filler is microcrystalline cellulose, and the content of the microcrystalline cellulose is 10% to 50%, preferably 30% to 50%, all in mass percentages.
7. The solid tablet for oral administration according to claim 4, wherein the filler is a combination of lactose and microcrystalline cellulose, and the contents of the lactose and the microcrystalline cellulose are 0% to 70% and 0% to 50%, preferably 40% to 60% and 4% to 10%, respectively, all in mass percentages.
8. The solid tablet for oral administration according to claim 3, wherein the binder is selected from starch, hypromellose, polyvinylpyrrolidone, sodium carboxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, gelatin, sucrose, and any combination thereof.
9. The solid tablet for oral administration according to claim 8, wherein the binder is hypromellose, and the content of the hypromellose is 0% to 10%, preferably 0% to 5%, all in mass percentages.
10. The solid tablet for oral administration according to claim 3, wherein the disintegrant is selected from sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, crospovidone, croscarmellose sodium, croscarmellose, methyl cellulose, pre gelatinized starch, sodium alginate, and any combination thereof.
11. The solid tablet for oral administration according to claim 10, wherein the disintegrant is croscarmellose sodium, and the content of the croscarmellose sodium is 0.5% to 5%, preferably 1% to 3%, all in mass percentages.
12. The solid tablet for oral administration according to claim 3, wherein the wetting agent is sodium lauryl sulfate, and the content of the sodium lauryl sulfate is 0% to 5%, preferably 0.5% to 1.0%, all in mass percentages.
13. The solid tablet for oral administration according to claim 3, wherein the glidant is selected from powdered cellulose, magnesium trisilicate, colloidal silica, talc powder, and any combination thereof.
14. The solid tablet for oral administration according to claim 13, wherein the glidant is colloidal silica, and the content of the colloidal silica is 0.1% to 20%, preferably 4% to 8%, all in mass percentages.
15. The solid tablet for oral administration according to claim 3, wherein the lubricant is selected from zinc stearate, glyceryl monostearate, glyceryl palmitate stearate, magnesium stearate, sodium fumarate stearate, and any combination thereof.
16. The solid tablet for oral administration according to claim 15, wherein the lubricant is magnesium stearate, and the content of the magnesium stearate is 0.1% to 2%, preferably 0.3% to 1%, all in mass percentages.
17. The solid tablet for oral administration according to any one of claims 1 to 16, wherein the solid tablet for oral administration further comprises a coating agent selected from an Opadry film coating powder, polyvinyl alcohol, hydroxypropyl cellulose, polyethylene glycol, and any combination thereof, preferably an Opadry film coating powder.
18. A method for preparing the solid tablet for oral administration according to any one of claims 1 to 17, wherein the granulation method of the solid tablet for oral administration is selected from direct powder compression, dry granulation, and wet granulation, preferably wet granulation.
19. A method for preparing the solid tablet for oral administration according to any one of claims 1 to 17, comprising the following steps:
(1) mixing the zanubrutinib and one or more excipients;
(2) subjecting the mixture of the zanubrutinib and one or more excipients to wet granulation with purified water, or an organic reagent, or an aqueous solution or an organic solution containing a binder, followed by drying and sizing;
(3) optionally, mixing the sized granules with an additional excipient and compressing them into plain tablets;
(4) optionally, coating the plain tablets,
wherein, if step (3) is not performed, the sized granules obtained in step (2) are compressed into plain tablets.
20. The method according to claim 19, wherein the organic reagent in step (2) is selected from ethanol, acetone, and a combination thereof.
21. The method according to claim 19 or 20, wherein the additional excipient in step (3) is selected from a filler, a lubricant, a glidant, and any combination thereof.
US17/617,530 2019-06-10 2020-06-10 Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor Abandoned US20220249491A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/090541 2019-06-10
CN2019090541 2019-06-10
PCT/CN2020/095352 WO2020249001A1 (en) 2019-06-10 2020-06-10 Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/095352 A-371-Of-International WO2020249001A1 (en) 2019-06-10 2020-06-10 Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/388,898 Continuation US20240075039A1 (en) 2019-06-10 2023-11-13 Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor

Publications (1)

Publication Number Publication Date
US20220249491A1 true US20220249491A1 (en) 2022-08-11

Family

ID=73781786

Family Applications (2)

Application Number Title Priority Date Filing Date
US17/617,530 Abandoned US20220249491A1 (en) 2019-06-10 2020-06-10 Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
US18/388,898 Pending US20240075039A1 (en) 2019-06-10 2023-11-13 Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/388,898 Pending US20240075039A1 (en) 2019-06-10 2023-11-13 Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor

Country Status (6)

Country Link
US (2) US20220249491A1 (en)
EP (1) EP3981399A4 (en)
JP (1) JP2022538214A (en)
CN (1) CN113939289A (en)
TW (1) TW202112376A (en)
WO (1) WO2020249001A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11591340B2 (en) 2016-08-16 2023-02-28 Beigene Switzerland Gmbh Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060420T2 (en) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
EP3160505A4 (en) 2014-07-03 2018-01-24 BeiGene, Ltd. Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
CN112057427A (en) * 2019-06-10 2020-12-11 百济神州(苏州)生物科技有限公司 Oral solid tablet containing Bruton's tyrosine kinase inhibitor and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2989106T3 (en) 2013-04-25 2017-03-20 Beigene Ltd CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEINKINASE INHIBITORS
WO2016123504A1 (en) * 2015-01-30 2016-08-04 Pharmacyclics Llc Btk inhibitor combinations and multidrug-resistance
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2017140254A1 (en) * 2016-02-19 2017-08-24 江苏恒瑞医药股份有限公司 Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
CN116478166A (en) * 2016-08-16 2023-07-25 百济神州(苏州)生物科技有限公司 Crystal form of compound, preparation and application thereof
AU2017313085A1 (en) * 2016-08-19 2019-03-14 Beigene Switzerland Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
CN108778281B (en) * 2016-11-25 2021-09-03 江苏恒瑞医药股份有限公司 Pyridone derivative pharmaceutical composition and preparation method thereof
JP2021517116A (en) * 2018-03-21 2021-07-15 エムイーアイ ファーマ，インク． Combination therapy
CA3224949A1 (en) * 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11591340B2 (en) 2016-08-16 2023-02-28 Beigene Switzerland Gmbh Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11814389B2 (en) 2016-08-16 2023-11-14 Beigene Switzerland Gmbh Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11851437B2 (en) 2016-08-16 2023-12-26 Beigene Switzerland Gmbh Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11884674B2 (en) 2016-08-16 2024-01-30 Beigene Switzerland Gmbh Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors

Also Published As

Publication number Publication date
WO2020249001A1 (en) 2020-12-17
EP3981399A1 (en) 2022-04-13
CN113939289A (en) 2022-01-14
JP2022538214A (en) 2022-09-01
TW202112376A (en) 2021-04-01
US20240075039A1 (en) 2024-03-07
EP3981399A4 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
US20220249491A1 (en) Oral solid tablet comprising bruton&#39;s tyrosine kinase inhibitor and preparation method therefor
US6531153B2 (en) Composition with sustained release of levodopa and carbidopa
JP5775464B2 (en) Delayed release oral dosage composition containing amorphous CDDO-ME
US11413295B2 (en) Oral preparation of obeticholic acid
US20220241285A1 (en) Oral capsule and preparation method therefor
RU2669351C1 (en) Film coated tablet containing choline alfoscerate and process for preparing same
TW201729812A (en) A pharmaceutical composition comprising JAK kinase inhibitor or its medicinal salt thereof
CN113925833A (en) Dosage form compositions comprising tyrosine protein kinase inhibitors
MX2009002336A (en) Imatinib compositions.
WO2021238978A1 (en) Pharmaceutical composition containing nitroxoline prodrug, and preparation method and application therefor
CA2874779A1 (en) Pharmaceutical composition of entecavir and process of manufacturing
CN109875972B (en) Olmesartan medoxomil and amlodipine pharmaceutical composition
CN106139156B (en) A kind of pharmaceutical composition containing quinoline or its salt
CN103520169A (en) Mirtazapine tablet and preparation method thereof
US10583087B2 (en) Pharmaceutical composition for oral administration
US20190054025A1 (en) Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
JP4999297B2 (en) High content terbinafine hydrochloride small tablets
CN104758266B (en) A kind of felodipine sustained-release tablets and its preparation technology
CN112057427A (en) Oral solid tablet containing Bruton&#39;s tyrosine kinase inhibitor and preparation method thereof
CN112168796A (en) Controlled-release drug sustained-release preparation of biphasic sustained-release system and preparation method thereof
KR101910707B1 (en) Metformin Extended-release Tablets Having Enhanced Patient Compliance and its Preparing Method
JPWO2019230937A1 (en) Oral solid preparation with excellent dissolution
CN103768034A (en) Sustained or controlled release solid composition comprising bupropion hydrochloride
KR20230009327A (en) Immediate release preparations comprising tenofovir alafenamide with improved formulation stability
CN109700778A (en) A kind of cinacalcet hydrochloride quick releasing formulation and preparation method thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: BEIGENE SWITZERLAND GMBH, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BEIGENE, LTD.;REEL/FRAME:060292/0066

Effective date: 20220503

Owner name: BEIGENE, LTD., CAYMAN ISLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:QIU, GANG;SHEN, YIWEI;FAN, WENYUAN;AND OTHERS;SIGNING DATES FROM 20201104 TO 20201211;REEL/FRAME:060291/0914

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION